Bristol-Myers Squibb: Colorectal Neoplasms trials

The registry lists 24 Colorectal Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 3 are open to participants now and 9 have results posted.

Phase 1 14Phase 2 14Phase 3 5No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT07223047Phase 1/2
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerRecruitingNCT07221357Phase 2/3
• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsRecruitingNCT06764771Phase 1
• A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsTerminatedNCT06024174Phase 1/2Results posted
• A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerTerminatedNCT05328908Phase 3Results posted
• A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Active, not recruitingNCT04008030Phase 3Results posted
• An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has SpreadCompletedNCT03414983Phase 2/3Results posted
• An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results posted
• A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsCompletedNCT03184870Phase 1/2Results posted
• Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal CancerCompletedNCT02103062Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal CancerTerminatedNCT01032291Phase 2Results posted
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results posted
• A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsActive, not recruitingNCT06730750Phase 1/2
• A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsActive, not recruitingNCT06544655Phase 1
• A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayTerminatedNCT05578092Phase 1
• A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)CompletedNCT05420909
• Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)Active, not recruitingNCT04793958Phase 3
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingNCT03785249Phase 1/2
• Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck CancerCompletedNCT02110082Phase 1
• Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal CancerCompletedNCT01086267Phase 1/2
• Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal CancerCompletedNCT00851045Phase 2
• Phase I/II Combination With Irinotecan- ErbituxCompletedNCT00594984Phase 1/2
• BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal MalignanciesCompletedNCT00207051Phase 1
• A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal CancerTerminatedNCT00040391Phase 2